+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


  • PDF Icon


  • 10 Pages
  • December 2018
  • Region: Global
  • Citeline
  • ID: 4775096
Drug Overview
Pfizer’s PF-06482077 is a 20-valent pneumococcal conjugate vaccine, which is currently in Phase II development in the US and EU. PF-06482077 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as seven additional serotypes.

Analyst Outlook
The broad serotype coverage of PF-06482077 (20-valent pneumococcal conjugate vaccine; Pfizer) gives it significant market potential, but it needs to demonstrate at least non-inferior immunogenicity to Prevnar 13 (13-valent pneumococcal conjugate vaccine; Pfizer) in Phase II studies.

Table of Contents

Drug Overview
Product Profiles
PF-06482077 : Pneumococcal vaccines

Table 1: PF-06482077 drug profile
Table 2: Trials of PF-06482077 for pneumococcal vaccination
Table 3: PF-06482077 for pneumococcal vaccination – SWOT analysis